NIT
APLS

NumerixS Investment Technologies’s Apellis Pharmaceuticals APLS Stock Holding History

NumerixS Investment Technologies’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,854
Closed -$50K – 1059
2020
Q1 		$50K Buy
+1,854
New +$65.8K 0.03% 606

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

NumerixS Investment Technologies's APLS Position: Q2 2020 in Review

NumerixS Investment Technologies sold out of Apellis Pharmaceuticals (APLS) in Q2 2020, closing a stake of 1,854 shares — an estimated $50K sold.

NumerixS Investment Technologies first reported a position in APLS in Q1 2020 and held it in 1 quarter. The position peaked at $50K in Q1 2020. 142 funds tracked by Wall St. Rank hold APLS as of Q2 2020.

  • NumerixS Investment Technologies reported no remaining Apellis Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • NumerixS Investment Technologies sold 1,854 Apellis Pharmaceuticals shares in Q2 2020, an estimated $50K.
  • NumerixS Investment Technologies first reported a position in Apellis Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • NumerixS Investment Technologies's Apellis Pharmaceuticals position peaked at $50K in Q1 2020.
  • 142 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2020.

Based on NumerixS Investment Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.